Skip to main content

Table 6 Hepatic lipid profile effects of EZ and piperine using PIU method

From: Characterization and interactions between piperine and ezetimibe in their Anti-hyperlipidemic efficacy using Biopharmaceutics and Pharmacokinetics

Group

TG (µmol/L)

TC (µmol/L)

SGOT (U/mmol)

SGPT (U/mmol)

ALP (U/mmol)

I

28.63 ± 0.26

15.63 ± 0.95

28.73 ± 0.12

30.59 ± 0.94

7.53 ± 0.21

II

46.95 ± 0.41

38.95 ± 0.86

79.41 ± 0.69

90.53 ± 0.57

15.94 ± 0.36

III

40.31 ± 0.35

26.74 ± 0.76

40.67 ± 0.45

45.76 ± 0.64

5.36 ± 0.51

IV

35.64 ± 0.11

20.48 ± 0.58

35.69 ± 0.21

40.11 ± 0.25

6.89 ± 0.42

V

25.94 ± 0.26

18.95 ± 0.64

35.42 ± 0.37

36.93 ± 0.31

4.97 ± 0.31

VI

19.46 ± 0.31

15.34 ± 0.31

26.49 ± 0.15

35.46 ± 0.12

4.02 ± 0.25

VII

15.42 ± 0.19

10.26 ± 0.11

20.87 ± 0.41

22.13 ± 0.42

3.16 ± 0.61